Why Adaptimmune Therapeutics Stock Sank and Then Quickly Rebounded Today
Shares of the clinical-stage biotech Adaptimmune Therapeutics (NASDAQ: ADAP) fell by as much as 11% immediately out of the gate Monday morning. The drugmaker's stock kicked off the week off on a sour note thanks to a fairly large public offering consisting of 12.5 million of its American depositary shares.
However, Adaptimmune has sharply rebounded as today's trading session has unfolded: As of 11:44 a.m. EDT, the biotech's stock is currently up by 19%.
Image source: Getty Images.
Source Fool.com
